Innovations in HIV Therapeutics 2022 - Asia-Pacific Edition

The advent of the COVID-19 pandemic has drastically changed the delivery of HIV care, but there is more on the horizon. New compounds with diverse modes of action and novel formulations have the potential to revolutionize HIV service delivery even more, as these may allow longer dosing schedules, increase adherence and improve cost-efficacy. Therefore, there is a continuous need for medical education on new (long-acting) antiretroviral therapies (ART), novel formulations, and devices to provide the best care. In contrast to existing educational activities that focus on approved or late-stage clinical data on ART, this program offers a platform entirely dedicated to HIV preclinical and early clinical development. This platform considered regional differences in health care systems, with a focus on the Asia-Pacific region.

The Innovations in HIV Therapeutics - Asia Pacific Edition took place as a virtual meeting on 16 December 2022.

As the pipeline of HIV drugs continues to evolve and novel formulations and devices are on the horizon, the Innovation in HIV Therapeutics meeting provided a scientific program that keeps HIV-treating clinicians, pharmacologists, and virologists updated on the latest data present in preclinical and early clinical development. New formulations, novel compounds, and their modes of action were presented, as well as their pharmacological properties, potential drug-drug interactions, and possible toxicities.

This meeting was presented as a one-day program accounting for the unique regional differences present in the Asia Pacific region.

General Information 

Practical Information 

Financial backing helps us deliver an impactful meeting experience to the benefit of healthcare professionals and community representatives involved in Innovations and HIV Treatment.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
 
To show your commitment to the cause and get in touch with us for a tailored support package, please contact Ms. Olivia Zhang at olivia.zhang@amededu.com or call +31 30 230 7140.
 
Benefits of Support
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

• Symposium opportunities
• Non-commercial interviews with company representatives
• Verbal acknowledgment during the program 
• Discounted and complimentary registrations for your representatives
• Company acknowledgment on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
• Digital and printed advertising opportunities 
• Social media shout-outs

*Subject to the support level.

Innovations in HIV Therapeutics - Asia Pacific Edition is accredited by the following societies. To claim the CME points, members of the societies must log on to the virtual congress portal and attend the full sessions. Additional information such as membership number or license number might be required after the event.

Innovations in HIV Therapeutics - Asia Pacific Edition is accredited by the Hong Kong Academy of Medicine (HKAM) up to 3 credits. To claim the CME points, members of the HKAM must log on to the virtual congress portal and attend the full sessions. 

Innovations in HIV Therapeutics - Asia Pacific Edition is accredited by the Infectious Diseases Association of Thailand (IDAT) up to 3.25 credits. To claim the CME points, members of the IDAT must log on to the virtual congress portal and attend the full sessions.